Lipoxen to Develop Improved Delivery of Antiviral Drugs for the Treatment of Liver Disease caused by Hepatitis C
Lipoxen joins with Nottingham University to deliver antiviral drugs direct to the liver by means of nanoparticles for the treatment of viral hepatitis
06-Nov-2008 -
Lipoxen PLC announced that it has entered into a research agreement with the University of Nottingham to develop new enhanced fomulations of antiviral drugs for the treatment of important liver diseases such as viral hepatitis which is caused by hepatitis C (HCV). The two parties will use novel ...
Boehringer Ingelheim
interferon
lung diseases
+4